Catalyst Capital Advisors’s Pfizer PFE Stock Holding History

Catalyst Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-88,000	Closed	-$4.51M	–	336
2022 Q4	$4.51M	Sell	88,000 -2,550	-3%	-$122K	0.15%	66
2022 Q3	$3.96M	Sell	90,550 -2,150	-2%	-$104K	0.15%	69
2022 Q2	$4.86M	Buy	+92,700	New	+$4.72M	0.2%	63
2019 Q2	–	Sell	-421,600	Closed	-$17M	–	463
2019 Q1	$17M	Sell	421,600 -17,707	-4%	-$709K	0.59%	24
2018 Q4	$18.2M	Buy	439,307 +233,777	+114%	+$9.7M	0.68%	14
2018 Q3	$8.59M	Buy	+205,530	New	+$7.91M	0.28%	60
2015 Q1	–	Sell	-759	Closed	-$22K	–	516
2014 Q4	$22K	Buy	+759	New	+$21.8K	﹤0.01%	376
2014 Q2	–	Sell	-104,784	Closed	-$3.19M	–	407
2014 Q1	$3.19M	Buy	104,784 +20,906	+25%	+$623K	0.72%	48
2013 Q4	$2.44M	Buy	+83,878	New	+$2.44M	0.79%	55

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Catalyst Capital Advisors's PFE Position: Q1 2023 in Review

Catalyst Capital Advisors sold out of Pfizer (PFE) in Q1 2023, closing a stake of 88,000 shares — an estimated $4.51M sold.

Catalyst Capital Advisors first reported a position in PFE in Q4 2013 and held it in 9 quarters. The position peaked at $18.2M in Q4 2018. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

Catalyst Capital Advisors reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
Catalyst Capital Advisors sold 88,000 Pfizer shares in Q1 2023, an estimated $4.51M.
Catalyst Capital Advisors first reported a position in Pfizer in Q4 2013 and held it in 9 quarters.
Catalyst Capital Advisors's Pfizer position peaked at $18.2M in Q4 2018.
3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Catalyst Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.